1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,545 | 0,685 | 06.02. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.01. | Micro-Cap Genenta Stock Reacts To Its Big Pivot From Biotech To Defense Investments | 3 | Benzinga.com | ||
| 27.01. | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 3 | SEC Filings | ||
| 27.01. | GENENTA SCIENCE SPA: Genenta Announces Strategic Transformation into a Biotech, Defense, Aerospace, and National Security Industrial Consolidator | 274 | GlobeNewswire (Europe) | Building on Biotech Heritage, Expanding into Defense and National Security Through Industrial Integrations of Privately Held Specialized Italian CompaniesATC - a Defense-Sector Company: First Industrial... ► Artikel lesen | |
| 19.12.25 | GENENTA SCIENCE SPA: Genenta Science Provides Update on CEO Ownership | 266 | GlobeNewswire (Europe) | MILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors... ► Artikel lesen | |
| 24.11.25 | Aktie von Genenta Science schießt nach Update zu Glioblastom-Studie in die Höhe | 11 | Investing.com Deutsch | ||
| GENENTA SCIENCE Aktie jetzt für 0€ handeln | |||||
| 24.11.25 | GENENTA SCIENCE SPA: Genenta Reports Long-Term Survival Trends and Immune Findings in Brain Tumor (GBM) Trial | 313 | GlobeNewswire (Europe) | MILAN, Italy and NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage biotechnology company developing a cell-based platform for targeted delivery of therapeutic... ► Artikel lesen | |
| 28.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.10.25 | Aktie von Genenta Science stürzt nach 15-Millionen-Dollar-Kapitalerhöhung ab | 13 | Investing.com Deutsch | ||
| 27.10.25 | Genenta Science stock plunges after $15 million ADS offering | 2 | Investing.com | ||
| 27.10.25 | Genenta Science jumps on $15M direct offering | 3 | Seeking Alpha | ||
| 27.10.25 | Genenta Science raises $15 million in ADS offering at $3.50 per share | 4 | Investing.com | ||
| 27.10.25 | GENENTA SCIENCE SPA: Genenta Announces Pricing of $15.0 Million Registered Direct Offering of American Depositary Shares | 2 | GlobeNewswire (USA) | ||
| 24.10.25 | Genenta Science Stock Jumps 85% On Strategic Collaboration With Anemocyte | 10 | RTTNews | ||
| 24.10.25 | Genenta Science stock soars on strategic LVV Plasmid DNA collaboration | 6 | Investing.com | ||
| 24.10.25 | Genenta and Anemocyte partner on lentiviral vector plasmid DNA tech | 17 | Investing.com | ||
| 24.10.25 | GENENTA SCIENCE SPA: Genenta and Anemocyte Announce Strategic Partnership to Advance Off-The-Shelf LVV Plasmid DNA Production | 1.587 | GlobeNewswire (Europe) | MILAN, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer Company in immuno-oncology, and ANEMOCYTE, a leading provider of advanced therapy and nucleic acids solutions, today... ► Artikel lesen | |
| 10.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 03.10.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 10.09.25 | Genenta Science S.p.A. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.05.25 | D.Boral Capital: Genenta Science Announces Participation in the D. Boral Capital Inaugural Global Conference | 261 | Newsfile | Milan, Italy and New York, New York--(Newsfile Corp. - May 8, 2025) - Genenta Science, SpA (NASDAQ: GNTA), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 319,57 | +4,56 % | Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| QIAGEN | 43,170 | -0,70 % | Diagnostikkonzern Qiagen überrascht im Schlussquartal - Weiteres Wachstum 2026 | VENLO/HILDEN (dpa-AFX) - Qiagen hat 2025 von einer anziehenden Nachfrage nach seinen Kernprodukten profitiert. Dabei lief das Schlussquartal besser als vom Labordienstleister und Diagnostikkonzern... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 72,90 | +0,11 % | Avidity Biosciences, Inc. - 8-K, Current Report | ||
| TARSUS PHARMACEUTICALS | 64,62 | +4,24 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements | Delivered quarterly XDEMVY® net sales of approximately $119 million, up approximately 147% year-over-year Weekly multi-patient prescribers grew approximately 30% in the third quarter underscoring... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,990 | +8,23 % | H.C. Wainwright reiterates Buy rating on Summit Therapeutics stock | ||
| ERASCA | 12,290 | +3,45 % | Erasca, Inc.: Erasca Announces Pricing of Upsized Public Offering of Common Stock | SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,960 | +11,24 % | Recursion Pharmaceuticals, Inc.: Positive Phase 1b/2 Results from Ongoing REC-4881 TUPELO Trial Demonstrate Rapid and Durable Reductions in Polyp Burden in Familial Adenomatous Polyposis (FAP) at 25 Weeks | REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median reduction after 12 weeks of treatment (n=12)After 12 weeks... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 62,19 | +0,10 % | Jefferies lowers Apogee Therapeutics stock price target on OX40 concerns | ||
| IMMUNOVANT | 27,040 | +12,39 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025 | IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 74,96 | +2,39 % | Structure Therapeutics Inc.: Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity | SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,770 | +5,53 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics' Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) "Research of the Year" Roundup | - Launch-HTN, the largest trial of an aldosterone synthase inhibitor conducted among participants with uncontrolled or treatment-resistant hypertension, was one of nine studies selected as most impactful... ► Artikel lesen | |
| LIMINATUS PHARMA | 1,840 | -10,24 % | Liminatus Pharma, Inc. - 8-K, Current Report | ||
| DAY ONE BIOPHARMACEUTICALS | 11,410 | +8,87 % | Day One Biopharmaceuticals, Inc.: Day One Announces Preliminary 2025 OJEMDA Net Product Revenue And Provides 2026 Net Product Revenue Guidance | Preliminary 2025 net product revenue of $155.4 million, representing 172% year-over-year growth; OJEMDA 2026 U.S. net product revenue projected to be $225 - $250 million Company to present on corporate... ► Artikel lesen | |
| AMYLYX PHARMACEUTICALS | 13,980 | +7,62 % | Gubra A/S: Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra | AMX0318 selected as development candidate after meeting key criteria, demonstrating a robust chemical stability profile, strong in vitro potency, evidence of in vivo efficacy and tolerability, high... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 25,360 | +1,40 % | Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
GENENTA SCIENCE SPA ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,105 (-16,03 %) liegt der Kurs bei 0,550 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GENENTA SCIENCE SPA ADR finden Sie auf Wallstreet Online.